Searching for new strategies against polymicrobial biofilm infections: guanylated polymethacrylates kill mixed fungal/bacterial biofilms
Open Access
- 21 October 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 71 (2) , 413-421
Abstract
Biofilm-related human infections have high mortality rates due to drug resistance. Cohabitation of diverse microbes in polymicrobial biofilms is common and these infections present additional challenges for treatment compared with monomicrobial biofilms. Here, we address this therapeutic gap by assessing the potential of a new class of antimicrobial agents, guanylated polymethacrylates, in the treatment of polymicrobial biofilms built by two prominent human pathogens, the fungus Candida albicans and the bacterium Staphylococcus aureus. We used imaging and quantitative methods to test the antibiofilm efficacy of guanylated polymethacrylates, a new class of drugs that structurally mimic antimicrobial peptides. We further compared guanylated polymethacrylates with first-line antistaphylococcal and anti-Candida agents used as combinatorial therapy against polymicrobial biofilms. Guanylated polymethacrylates were highly effective as a sole agent, killing both C. albicans and S. aureus when applied to established polymicrobial biofilms. Furthermore, they outperformed multiple combinations of current antimicrobial drugs, with one of the tested compounds killing 99.98% of S. aureus and 82.2% of C. albicans at a concentration of 128 mg/L. The extracellular biofilm matrix provided protection, increasing the MIC of the polymethacrylates by 2–4-fold when added to planktonic assays. Using the C. albicans bgl2ΔΔ mutant, we implicate matrix polysaccharide β-1,3 glucan in the mechanism of protection. Data for two structurally distinct polymers suggest that this mechanism could be minimized through chemical optimization of the polymer structure. Finally, we demonstrate that a potential application for these polymers is in antimicrobial lock therapy. Guanylated polymethacrylates are a promising lead for the development of an effective monotherapy against C. albicans/S. aureus polymicrobial biofilms.Keywords
Funding Information
- National Health & Medical Research Council of Australia (APP1066647)
- Monash University Interdisciplinary Research
- Australian Research Council (ARC)
- ARC DECRA
- CSIRO's
This publication has 47 references indexed in Scilit:
- Mixed bloodstream infections involving bacteria and Candida spp.Journal of Antimicrobial Chemotherapy, 2013
- Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010Infection Control & Hospital Epidemiology, 2013
- Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infectionsClinical Microbiology and Infection, 2013
- Clinical significance and outcome of polymicrobial Staphylococcus aureus bacteremiaJournal of Infection, 2012
- Comparison of the two blood culture systems, Bactec 9240 and BacT/Alert 3D, in the detection of Candida spp. and bacteria with polymicrobial sepsisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007Infection Control & Hospital Epidemiology, 2008
- Biofilms and Chronic InfectionsJAMA, 2008
- Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literatureDiagnostic Microbiology and Infectious Disease, 2007
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- Candida SepsisArchives of Surgery, 1985